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Vaccination is the most effective method to date to prevent viral diseases. It intends to
mimic a naturally occurring infection while avoiding the disease, exposing our bodies to
viral antigens to trigger an immune response that will protect us from future infections.
Among different strategies for vaccine development, recombinant vaccines are one
of the most efficient ones. Recombinant vaccines use safe viral vectors as vehicles
and incorporate a transgenic antigen of the pathogen against which we intend to
generate an immune response. These vaccines can be based on replication-deficient
viruses or replication-competent viruses. While the most effective strategy involves
replication-competent viruses, they must be attenuated to prevent any health hazard
while guaranteeing a strong humoral and cellular immune response. Several attenuation
strategies for adenoviral-based vaccine development have been contemplated over
time. In this paper, we will review them and discuss novel approaches based on the
principle that protein synthesis from individual genes can be modulated by codon usage
bias manipulation. We will summarize vaccine approaches that consider recoding of viral
proteins to produce adenoviral attenuation and recoding of the transgene antigens for
both viral attenuation and efficient viral epitope expression.
Keywords: codon optimization, viral attenuation, live-attenuated vaccines, adenovirus-based vaccines, codon
usage bias
INTRODUCTION
Adenoviruses are non-enveloped viruses with a double-stranded DNA genome. They were first
discovered in 1953 by Rowe and colleagues (Huebner et al., 1954). Adenoviruses are broadly present
across vertebrate species and have been classified into five genera: Mastadenovirus, Aviadenovirus,
Siadenovirus, Atadenovirus, and Ichtadenovirus. Mastadenoviruses infect mammals and are
classified into 7 species (A–G) (Seto et al., 2011; Dhingra et al., 2019). None causes severe diseases
in humans and, therefore, they are not considered a serious health hazard.
Adenoviruses have icosahedral capsids of 70–100 nm. They are composed of 252 capsomeres,
with 12 pentons. Each penton contains a fiber. The capsid fiber is responsible for the recognition
and interaction with the host cell. Adenoviral replication and transcription take place in the
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nucleus of the host infected cell where viral DNA is first
translocated through the nuclear pore associated with its core
proteins (Charman et al., 2019; Figure 1). Adenoviruses have
mid-sized DNA genomes (30–40 kb), with genes encoded in both
strands, and an extensive use of alternative splicing (Donovan-
Banfield et al., 2020). Adenoviruses present highly orchestrated
sequential gene expression, with early (E1A, E1B, E2A, E2B, E3,
and E4) and intermediate (IX and IVa) transcription units mostly
displaying regulatory functions. Early genes are also responsible
for inducing the Major Late Promoter, which activates the
transcription of late expression units (L1, L2, L3, L4, and L5) that
are processed by alternative splicing and encode the structural
proteins of the new virions (Figure 2).
Human adenoviruses exhibit a highly variable tissue tropism,
including the respiratory tract, gastrointestinal tract and
conjunctiva. Infections are typically caused by inhalation of
aerosolized droplets from infected individuals, conjunctival
inoculation, or fecal-oral contact. They usually cause mild
symptomatology such as cold-like symptoms, fever, sore throat,
acute bronchitis, pneumonia, diarrhea, or conjunctivitis in
patients. Even they are considered non-hazardous for the
general population, there is an FDA approved vaccine against
adenoviruses, consisting on an oral administration of live
Ad4 and Ad7 serotypes, exclusively used for the US military
personnel. This vaccine was developed to control an endemic
adenovirus infection at military training camps resulting in
the near elimination of Ad4/7 related disease (Broderick et al.,
2017). Currently, there is no approved vaccine for the general
population (Kuschner et al., 2013; Lion, 2014) with an ongoing
debate on whether it would be of general interest to develop a
vaccine for public use.
However, there is a growing interest for using adenoviruses
as scaffolds in vaccine production to fight a broad repertoire of
pathogens. Several key properties make them good candidates:
infect dividing and non-dividing cells, can be delivered both
systemically, or through mucosal surfaces, induce both innate
and adaptive immunity, follow a lytic cycle and are physically and
genetically stable. Even more importantly, adenoviruses are easy
to genetically engineer, allow high levels of transgene expression,
and are able to grow to high titers in vitro (Gao et al., 2019).
Adenovirus infection triggers the release of cytokines, generating
an inflammatory milieu in the infected tissue. This is the
consequence of the virus recognition by Pathogen Recognition
Receptors or the specific interaction between the adenoviral fiber
and the CAR receptor on the cell surface, activating a cascade
of events that induce cytokine release (Majhen et al., 2014).
In the infected cell, adenoviral replication and viral protein
expression when using replication-competent vectors triggers B
cell and CD4 + and CD8 + T cell responses against viral and
transgene proteins. This immune response can be a beneficial
effect in the vaccine context, where adenoviruses can act as
a natural adjuvant (Robert-Guroff, 2007). On the other hand,
a balanced innate immune response seems optimal to elicit
immunity as the induction of very high levels of type I interferon
upon dendritic cell infection can downregulate transgene
expression and the formation of optimal antibody responses
(Hensley et al., 2007).
ADENOVIRUS-BASED VACCINES
Adenovirus-based vaccines use replicating or non-replicating
virus as platforms to express the vaccinating antigen or epitope
(Figure 3). The antigen in the formulated adenovirus vaccines
can be present as a protein or as a transgene. If the adenovirus
contains the antigen as a protein, there is no need for gene
expression and the virus can be immunogenic even in the absence
of infectivity or transduction. Usually the virus is engineered
to display the antigen fused to a viral structural protein of
the capsid such as the hexon or the fiber (Vujadinovic and
Vellinga, 2018). This antigen display on the capsid allows
for the direct presentation of the antigen to B-cell receptors
(membrane antibodies) and the indirect presentation to T-cell
receptors. For the presentation and activation of T cells, the
virus is internalized and processed by antigen-presenting cells
(APCs) that load viral and vaccinating antigen peptides in the
MHC-I and MHC-II. Antigen display circumvents one of the
main limitations of viral vaccines: the presence of pre-existing
neutralizing antibodies that opsonize the virus and prevent
infection and gene expression. However, this approach is limited
by the amount of exogenous protein that the hexon or the fiber
can accommodate, restricting it to approximately 100 amino
acids. Thus, most of the conformational B-cell epitopes that are
not formed by contiguous protein sequences cannot be displayed
appropriately in the adenovirus capsid to generate antibodies.
As an alternative, the antigen can be encoded as a gene in
the virus. This approach requires the transgene expression in
APCs or in other cells that can indirectly provide the expressed
antigen to APCs. Once infected with adenoviruses, humans
develop neutralizing antibodies that preclude viral infection and,
consequently, transgene expression. In these seropositive hosts,
the gene-expression vaccine will not be effective. To solve this
limitation, vaccines can be developed from rare or low-prevalent
human serotypes such as HAd2, HAd26, HAd35, HAd48, or
HAd64 or from adenoviruses from non-human primates (Bots
and Hoeben, 2020; Garofalo et al., 2020). Nevertheless, in
the context of replication-competent vaccines, employing the
first strategy seems the safest option for vaccination, as non-
human virus zoonoses could potentially arise from the use
of adenoviruses from other animals (Bots and Hoeben, 2020;
Garofalo et al., 2020). Therefore, improving viruses such as HAd5
is a promising strategy in adenoviral-based vaccine development.
Viral shielding of Ad5 capsids with a variety of nanomaterials
such as PEG, or PBAEs among others have shown to provide
protection toward pre-existing Ad neutralizing antibodies (Hong
and Yun, 2019; Brugada-Vilà et al., 2020).
Another key issue to address when considering adenovirus-
based vaccines, as well as other virus-vectored vaccines, is the
viral immunodominance. A strong response against the virus
epitopes can mask the response against the vaccinating antigen
(Schöne et al., 2017). This occurs in naïve and in previously
exposed hosts. When the host has been previously exposed to
the virus and there are pre-existing memory B and T cells
immunodominance is aggravated. This immunodominance was
noted in a vaccination trial against HIV using adenoviruses
(Frahm et al., 2012). Moreover, eliciting a memory response will
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FIGURE 1 | Overview of the Adenovirus replication cycle. Early and late phases of the cycle are indicated. The viral DNA replication marks the progression from early
to late transition.
FIGURE 2 | Scheme of the adenoviral genome. The organization of the transcription units and encoded proteins are presented.
further dominate the breath of epitopes recognized. Again, this
can be solved using rare low-prevalent serotypes or non-human
adenoviruses, but cross-reactive immunity has been observed
that may reduce the efficacy of this approach (Frahm et al., 2012).
When repeated vaccination is required, a classical strategy to
palliate the viral vector immunodominant memory response is
the use of a different virus expressing the same antigen in the
second dose of the vaccine (the boost), known as heterologous
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FIGURE 3 | Replication-competent versus replication-deficient adenovirus encoding transgenic antigen. The scheme illustrates the amplification effect of
replication-competent adenovirus with the generation of new virions and increased antigen production. Antigen expressed from the adenovirus is shown in brown.
prime-boost. However, even in naïve hosts the virus can still
be immunodominant compared to the vaccinating antigen
(Schirmbeck et al., 2008). Immunodominance is associated
to a competition of responding immune cells for adenoviral
epitopes and antigen recognition. Several factors contribute to
immunodominance (Sadegh-Nasseri and Kim, 2019; Abbott and
Crotty, 2020). One key factor is the amount of antigen produced
(Quinn et al., 2015). Avoiding adenovirus gene expression using
gutless vectors as vaccines can prevent virus immunodominance
(Kron et al., 2011). In humans, immunodominant epitopes for
B and T cells are mainly present in capsid proteins, namely
the penton, hexon and fiber (Tischer et al., 2016). Codon
usage can be used as a strategy to increase the efficacy of a
replication-competent vaccine by increasing the relative levels
of the vaccinating antigen compared to the levels of these
immunodominant viral proteins but without decreasing virus
gene expression to preserve virus replication.
Successful recombinant vaccines based on the use of
replication-deficient adenoviruses have been developed over the
last years (reviewed in Majhen et al., 2014; Barouch et al., 2015).
Early developments were based on the deletion of the E1 region.
Further improvements in vectorization resulted with the deletion
of E1 and E3 regions what allows to accommodate transgenes of
approximately 7.5 Kb. Such vectors are stable, easy to manipulate
can be produced at high titers and they have shown safety and
immunogenicity in clinical trials (Coughlan, 2020).
Nowadays, during the SARS-CoV-2 pandemic, several
replication-defective adenoviruses expressing the spike
glycoprotein of the SARS-CoV-2 are in development. One
of them, based on the HAd5, (clinicaltrials.org, NCT04341389)
has shown tolerability and immunogenicity at 28 days post-
vaccination and could induce humoral and T cell immune
responses, activating both CD4 + and CD8 + T cells (Zhu
et al., 2020). Interestingly, the Ad5-nCoV vaccine has shown
a protective effect against SARS-CoV-2 challenge in wild-type
BALB/c mice and ferrets following intranasal immunizations,
highlighting the potential of the mucosal vaccination route
(Wu et al., 2020). A chimpanzee adenovirus-vectored vaccine
(ChAdOx1 nCoV-19) administered to 1,077 participants
showed an acceptable safety profile with the induction of both
humoral and cellular immune responses (Folegatti et al., 2020).
Another adenovirus-based vaccine against SARS-CoV-2 is under
development using Adenovirus serotype 26 (Ad26.COV2.S)
and it has shown that a single shot of the vaccine induces
protection in non-human primates (Mercado et al., 2020). At
present, this vaccine is being evaluated in clinical trials. A fourth
adenovirus vaccine against SARS-CoV-2 is ongoing, which
consists of two non-replicative adenoviruses based on Ad26 and
Ad5 expressing the spike glycoprotein (S) and implemented
in a prime-boost regimen. The vaccine was well tolerated and
produced humoral and cellular immune responses in healthy
adults (Logunov et al., 2020).
Despite the potential interest on replication-deficient
adenovirus-based vaccines, obtaining immuno-protection
usually requires high viral doses to elicit immunity. Adenovirus
vaccines based on fully-replicative viruses are able to expand
antigen expression and trigger improved immunity. However,
the potential of replication-competent adenoviruses as vectors
for immunization has been poorly explored to date. To preserve
safety, replicative-competent adenovirus vaccines need to
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be attenuated to avoid causing pathologies associated with
adenoviral infections. Therefore, a good balance between
antigen-transgene expression and adenoviral replication is
crucial to develop a successful vaccine.
Live attenuated viruses are typically variants of the wild-
type virus that have a reduced capacity to grow. Historically,
attenuation was achieved by culturing viruses using cells from
other species. Over time the virus would gain mutations
allowing it to better replicate in the new host. If administered
again to humans, the newly acquired mutations would then
have a detrimental effect on viral replication resulting in a
human attenuated virus (Smith, 2012). This technique was time-
consuming and made it difficult to select and isolate the proper
attenuated candidate.
More rational strategies for virus attenuation in vaccine
development have been in the spotlight of many researchers in
recent years as they allowed for more efficient, specific, and safe
vaccine development. Strategies based on genetic engineering of
the viral genome have been studied. A group of these strategies
include the deletion of dispensable transcription units. This
also facilitates the accommodation of transgenic antigens, since
for efficient viral packaging, the insertion of foreign sequences
into the intact adenoviral genome is limited to around 1.8 Kb.
Deletion of E3, which encodes gene products non-essential for
viral replication has been commonly used. In these vaccines, the
E3 promoter or the Major Late Promoter if splice acceptors are
maintained or even stronger promoters such as the CMV drive
the expression of the transgenes. One example is the Ad4-H5-Vtn
vaccine in which the expression of the influenza hemagglutinin
gene in the E3-deleted adenovirus serotype 4 genome induced
protective immunity against H5N1 influenza virus infection
in mice intranasally immunized (Alexander et al., 2012). Oral
vaccination with Ad4-H5-Vtn, in a phase I clinical trial, resulted
in no serious adverse event suggesting its potential as a priming
vaccine (Gurwith et al., 2013). Another example of attenuation
of replicative- competent adenoviruses by means of viral gene
deletion is the replication-competent Ad26 with the E3 and E4
regions deleted generated as vector to develop candidate HIV-1
vaccines (Maxfield et al., 2015). Which deletion is most suitable
for an adenovirus vaccine may depend on different variables such
as the size of the insert or the virus serotype among others.
Additional strategies for viral attenuation rely on genome
modifications to restrict adenoviral replication to specific
cells by the use of miRNAs or tissue-specific promoters to
modulate viral gene expression and tropism or the retargeting
of adenovirus toward dendritic cells to increase antigen
presentation (Tatsis and Ertl, 2004; Bofill-De Ros et al., 2015).
In general, replication-competent adenovirus vaccines lead to
high transgene expression and require lower doses to confer
persistent immunity. However, a good balance between the
amount of the vaccinating antigen and the immunodominance
of viral epitopes needs to be achieved to generate specificity
in the immune response. In this regard, single-cycle replicating
adenovirus have shown to amplify transgene expression. These
vaccines replicate its DNA, and the transgene but incorporate a
deletion that does not permit virion production (Crosby et al.,
2015). Alternatively, codon optimization of viral proteins and
transgenes in order to maximize transgene expression while
controlling adenoviral protein expression could be considered
as a novel approach. This could boost adenovirus-based vaccine
development opportunities.
SYNONYMOUS GENE RECODING FOR
VIRAL ATTENUATION IN ADENOVIRUS
VACCINE DEVELOPMENT
The genetic code is redundant, with eighteen out of twenty amino
acids being encoded by two, four, or six synonymous codons.
The frequency in which synonymous codons are used differs
from what would be expected by chance, with some being rarely
used and others more frequently. This phenomenon, known
as codon usage bias, happens to be species-specific (Grantham
et al., 1980; Pouwels and Leunissen, 1994) and is described to
correlate with the relative abundance of iso-accepting tRNAs
(i.e., the tRNAs that are associated with the same amino
acid but recognize different codons). The correlation between
specific tRNA abundance and codon usage could determine how
efficiently particular transcripts are translated. In this way, codon
optimality is correlated with how efficiently codons are decoded
by ribosomes and thus, protein synthesis levels. The third base
position in a codon (GC3) or (AT3) has been recently linked
to human mRNA stability showing that GC3 codons stabilize
mRNA while AT3 codons destabilize mRNA. Thus leading to
consider GC3 codons and AT3 codons as optimized and de-
optimized, respectively (Hia et al., 2019). Due to the inherent
viral dependence on cellular translational machinery, viral codon
usage is, in many cases, considered as the result of mutational
and selective pressure determined by the tRNA pool of the
host cell (Duret, 2002; Das et al., 2005; Chamary et al., 2006;
Hershberg and Petrov, 2008).
Substitution of synonymous codons based on the differential
codon usage in a given organism has been used as a strategy
to optimize or deoptimize the expression of viral proteins.
Altering the codon usage of a virus by codon deoptimization
has been widely explored for vaccine development against
HIV, Lassa Virus, or Influenza virus among others (Mueller
et al., 2006; Coleman et al., 2008; Cai et al., 2020). Codon
deoptimization of certain genes in the viral genome requires
the use of less abundant or rare tRNAs within the host tRNA
pool, leading to slower translation rates (Zhou et al., 1999;
Jack et al., 2017). This, results in a lower replicative viral
fitness while maintaining a strong immune response and, due to
the numerous mutations used to recode the engineered genes,
avoiding reversion to virulence. Furthermore, this approach can
be extended to consider not only the bias in codon usage, but
codon pair bias, which considers that there are higher chances
to find certain codons next to specific codons (Gutman and
Hatfield, 1989; Coleman et al., 2008; Gamble et al., 2016).
In this line, polioviruses for example have been attenuated
by recoding their genomes with underrepresented codon pairs
(Coleman et al., 2008). This attenuation strategies can work for
both DNA and RNA viruses and are commonly used nowadays
(Martínez et al., 2019).
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Despite of the fact that codon deoptimization is a well-
established general strategy for viral attenuation, there are no
adenovirus-based vaccines attenuated via codon recoding. In
fact, recent studies suggest that codon optimization, instead of
deoptimization, could be a potential strategy for adenovirus
attenuation (Villanueva et al., 2016). In the context of replication-
competent vectors, the codon recoding strategy should take
into account an attenuated virus replication and the relative
increase in antigen production compared to viral proteins.
Experimental results after codon optimization of the adenoviral
fiber in a non-viral system showed increased protein expression,
reinforcing the importance of using optimal codons adapted
to the host codon usage for efficient gene expression in non-
viral contexts. Conversely, codon-optimized fiber expression, as
well as the expression of other late proteins, were attenuated
in a viral context, impairing viral fitness, thus leading to an
attenuated adenovirus. We speculate that this attenuation is the
result of a competition for a limiting pool of aminoacylated-
tRNAs. Aminoacylated-tRNAs could then act as a limiting
resource during the late phase of the viral replication cycle,
which involves exceptionally high gene expression levels
(Villanueva et al., 2016).
Following this argument, the introduction of transgenes using
the same codons as other structural proteins could generate
an intergenic competition resulting in the loss of viral fitness
(Villanueva et al., 2016). Indeed, an extreme optimization of a
transgene could break the balance between the overall codon
usage and the tRNA concentrations and affect the expression of
other genes (Qian et al., 2012). This is considered detrimental
for virotherapy and links to the observation that in most
clinical trials involving armed oncolytic viruses (where the
aim is to obtain high levels of transgene and viral particles)
the codon usage of the transgene is suboptimal (Núñez-
Manchón et al., 2020). We have recently targeted this question
showing that, when expressing highly optimized transgenes,
the transgene is highly expressed during the first round of
infection, but its expression negatively impacts viral fitness
(Núñez-Manchón et al., 2020). We have further shown how,
by deoptimizing the transgene codon usage, both the viral
and transgene protein expression can be balanced, generating
highly replicative antitumor viruses expressing therapeutic genes.
From the adenoviral-based vaccine-development perspective,
intergenic competition opens new and exciting opportunities
where the transgene expression can be boosted while attenuating
adenoviral replication. Therefore, optimization of the codon
usage of the transgene could have a double impact resulting both
in viral attenuation and in an increase of the engineered epitope
expression (Figure 4).
Protein recoding to modify either viral proteins or transgene
antigens should carefully consider that synonymous codon
changes may affect protein conformation and stability or even
alter protein function. Synonymous codons have been shown to
contribute differently to the secondary structures of the resulting
protein (Buhr et al., 2016) and most complex structures may
contain non-preferred codons that are translated slower and,
therefore, allow ordered and sequential folding of the resulting
FIGURE 4 | Antigen-transgene recoding strategy for adenoviral-based vaccines. The scheme illustrates that codon optimization of the transgenic antigen induces its
high expression while attenuates adenovirus fitness. Antigen expressed from the adenovirus is shown in brown.
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protein. Therefore, when recoding viral genes, or other viral
epitopes for vaccine development, the immunogenicity of the
new engineered gene needs to be carefully determined.
Since tRNA availability is not the unique factor influencing
protein expression, several other aspects concerning gene
recoding are key for vaccine development (Brule and Grayhack,
2017). For example, the increase of CpG dinucleotides
frequency in both coding and non-coding regions has also been
demonstrated to attenuate RNA viruses early after cell entry by
preventing their replication (Burns et al., 2009; Atkinson et al.,
2014; Simmonds et al., 2015). Although little is known about the
biological mechanism that leads to attenuation, this last strategy
seems to be less effective than codon deoptimization (Groenke
et al., 2020), probably since it prevents a high expression of the
viral genes and any engineered transgene epitope.
Finally, attenuation of adenoviruses can have further
implications helping to overcome anti-adenovirus vector
immunity. Even if the immunogenicity of the adenovirus is
desirable since it can act as adjuvant triggering inflammation,
a too strong immunity could interfere with the specific antigen
immune response of the vaccine reducing their efficacy. Thus,
attenuation of adenovirus based-vaccines with synonymous
genes recoding of viral proteins or transgene-epitopes is
a promising strategy to favor specific antigen-transgene
immune response.
Codon optimization of the transgenic antigen in replication-
deficient adenovirus is a tested approach for increasing protein
expression. A recent example of this strategy is the prophylactic
vaccine against SARS-CoV-2 (Ad5-S-nb2) in which the S-coding
sequence of SARS-CoV-2, inserted in the E1 region of an E1/E3-
deleted Ad5 vector, was optimized by altering the codon usage
to efficiently express in human cells and (Feng et al., 2020). The
authors claim that the great potency of Ad5-S-nb2 may enable
the induction of protective immunity using low dosages what
could reduce side-effects. Several other examples have shown the
benefits of eliciting a high transgene-specific immune response by
applying codon-usage transgene optimization (Shoji et al., 2012;
Feng et al., 2018). However, in the development of DNA vaccines
codon optimization did not always positively correlate with
efficacy (Li and Petrovsky, 2016). The fact that mRNAs contain
multiple layers of information should be carefully considered by
codon optimization strategies to avoid potential undesired effects.
FUTURE PERSPECTIVES
The use of adenoviral vectors as vaccines against viral pathogens
is continuously growing and it is at the forefront of vaccinology.
While there are still some obstacles to overcome, novel
approaches are being developed that expand the field.
Codon deoptimization has proven to be a useful and
effective strategy for viral attenuation with different viruses.
In the context of replication-competent adenovirus-based
vaccines, synonymous recoding strategies have been poorly
explored but codon optimization of adenoviral proteins and/or
transgene antigens are showing good potential in vaccine
development. Such knowledge can lead to the development
of additional codon optimization strategies that can concert a
good balance between transgene antigen expression and virus
attenuation. However, the complexity of codon usage demands
a profound understanding of adenovirus-host interactions.
Moreover, vaccine manufacturing aspects should be taken into
account when introducing such modifications to enable large
scale productions that could meet the requirements for clinical
applications. Altogether emphasizes the need for future studies
that demonstrate the efficacy of transgene/adenoviral protein
recoding to position this strategy as a real alternative in
adenoviral-based vaccines.
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